Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.57M | 78.05M | 78.09M | 72.80M | 110.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.57M | 78.05M | 78.09M | 72.80M | 110.18M |
| Cost of Revenue | 43.63M | 42.64M | 41.05M | 39.84M | 90.54M |
| Gross Profit | 39.94M | 35.41M | 37.04M | 32.97M | 19.64M |
| SG&A Expenses | 109.49M | 114.79M | 116.26M | 119.87M | 132.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 252.27M | 251.37M | 245.55M | 252.02M | 317.25M |
| Operating Income | -168.70M | -173.32M | -167.46M | -179.22M | -207.07M |
| Income Before Tax | -187.47M | -190.56M | -200.54M | -221.18M | -250.14M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -187.47 | -190.56 | -200.54 | -221.18 | -250.14 |
| Earnings from Discontinued Operations | 342.44M | 370.31M | 69.61M | 249.69M | 249.69M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.97M | 179.75M | -130.94M | 28.51M | -450.00K |
| EBIT | -168.70M | -173.32M | -167.46M | -179.22M | -207.07M |
| EBITDA | -164.64M | -168.68M | -162.65M | -173.94M | -201.77M |
| EPS Basic | 1.33 | 1.54 | -1.13 | 0.27 | -0.01 |
| Normalized Basic EPS | -1.92 | -1.95 | -1.94 | -2.00 | -1.22 |
| EPS Diluted | 1.30 | 1.52 | -1.16 | 0.24 | -0.01 |
| Normalized Diluted EPS | -1.92 | -1.95 | -1.94 | -2.00 | -1.22 |
| Average Basic Shares Outstanding | 463.58M | 462.56M | 461.31M | 458.20M | 454.27M |
| Average Diluted Shares Outstanding | 463.58M | 462.56M | 461.31M | 458.20M | 454.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |